Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
muscular dystrophy
Biotech
PepGen gains a little pep in its step as FDA clears trial hold
A phase 1 study for PepGen’s myotonic dystrophy therapy has been cleared for launch in the U.S. after a five-month FDA clinical hold.
Annalee Armstrong
Oct 12, 2023 7:00am
Sanofi wagers $400M in biobucks to go after muscular dystrophy
Oct 4, 2022 8:00am
Cancer drug delays DMD progression in mice
Jul 1, 2022 3:10pm
BridgeBio plots path to market for muscular dystrophy drug
Mar 14, 2022 7:30am
Dewpoint snags $150M for programs with Pfizer, Merck and Bayer
Feb 3, 2022 6:00am
Sanofi-backed Expansion nabs $80M for RNA neurodegenerative work
Sep 29, 2021 7:00am